Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 615: Safety and PK of VRC01.23LS in Healthy Adults
NCT05627258Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2023
- Primary completion
- Jul 2024
- Modality
- Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, open-label trial of VRC01.23LS in human immunodeficiency virus infection (HIV) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms at 7 days, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms at 7 days and 4 more. Started Jan 2023; status: completed.
02
Drugs
VRC01.23LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05627258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627258.